| Patient-derived tumour xenografts as models for oncology drug development JJ Tentler, AC Tan, CD Weekes, A Jimeno, S Leong, TM Pitts, JJ Arcaroli, ... Nature reviews Clinical oncology 9 (6), 338-350, 2012 | 1365 | 2012 |
| Activation of gene expression in human neutrophils by high mobility group box 1 protein JS Park, J Arcaroli, HK Yum, H Yang, H Wang, KY Yang, KH Choe, ... American Journal of Physiology-Cell Physiology 284 (4), C870-C879, 2003 | 596 | 2003 |
| Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts A Capasso, J Lang, TM Pitts, KR Jordan, CH Lieu, SL Davis, JR Diamond, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 137 | 2019 |
| Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study J Mouchawar, C Korch, T Byers, TM Pitts, E Li, MRE McCredie, GG Giles, ... Cancer research 70 (12), 4795-4800, 2010 | 118 | 2010 |
| Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors TM Pitts, SL Davis, SG Eckhardt, EL Bradshaw-Pierce Pharmacology & therapeutics 142 (2), 258-269, 2014 | 110 | 2014 |
| Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development TM Pitts, AC Tan, GN Kulikowski, JJ Tentler, AM Brown, SA Flanigan, ... Clinical cancer research 16 (12), 3193-3204, 2010 | 93 | 2010 |
| Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer JJ Tentler, S Nallapareddy, AC Tan, A Spreafico, TM Pitts, MP Morelli, ... Molecular cancer therapeutics 9 (12), 3351-3362, 2010 | 91 | 2010 |
| Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models TM Pitts, M Morrow, SA Kaufman, JJ Tentler, SG Eckhardt Molecular cancer therapeutics 8 (2), 342-349, 2009 | 90 | 2009 |
| Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer A Spreafico, JJ Tentler, TM Pitts, AC Tan, MA Gregory, JJ Arcaroli, ... Clinical Cancer Research 19 (15), 4149-4162, 2013 | 76 | 2013 |
| Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors JR Diamond, BR Bastos, RJ Hansen, DL Gustafson, SG Eckhardt, ... Clinical Cancer Research 17 (4), 849-860, 2011 | 76 | 2011 |
| Involvement of phosphatidylinositol 3-kinase γ in neutrophil apoptosis KY Yang, J Arcaroli, J Kupfner, TM Pitts, JS Park, D Strasshiem, RP Perng, ... Cellular signalling 15 (2), 225-233, 2003 | 72 | 2003 |
| Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models SA Flanigan, TM Pitts, TP Newton, GN Kulikowski, AC Tan, MC McManus, ... Clinical cancer research 19 (22), 6219-6229, 2013 | 62 | 2013 |
| Development of new preclinical models to advance adrenocortical carcinoma research K Kiseljak-Vassiliades, Y Zhang, SM Bagby, A Kar, N Pozdeyev, M Xu, ... Endocrine-Related Cancer 25 (4), 437-451, 2018 | 60 | 2018 |
| Summary of the International Conference on Onco-Nephrology: an emerging field in medicine A Capasso, A Benigni, U Capitanio, FR Danesh, V Di Marzo, L Gesualdo, ... Kidney international 96 (3), 555-567, 2019 | 59 | 2019 |
| Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal … JJ Tentler, EL Bradshaw-Pierce, NJ Serkova, KM Hasebroock, TM Pitts, ... Clinical Cancer Research 16 (11), 2989-2998, 2010 | 57 | 2010 |
| Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models JR Diamond, SG Eckhardt, AC Tan, TP Newton, HM Selby, KL Brunkow, ... Clinical Cancer Research 19 (1), 291-303, 2013 | 53 | 2013 |
| Common PIK3CA mutants and a novel 3′ UTR mutation are associated with increased sensitivity to saracatinib JJ Arcaroli, KS Quackenbush, RW Powell, TM Pitts, A Spreafico, ... Clinical Cancer Research 18 (9), 2704-2714, 2012 | 53 | 2012 |
| A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer JR Diamond, SG Eckhardt, TM Pitts, A van Bokhoven, D Aisner, ... Breast Cancer Research 20, 1-10, 2018 | 52 | 2018 |
| Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer TM Pitts, TP Newton, EL Bradshaw-Pierce, R Addison, JJ Arcaroli, ... PloS one 9 (11), e113037, 2014 | 50 | 2014 |
| Targeting vascular endothelial growth factor receptor-1 and-3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines MP Morelli, AM Brown, TM Pitts, JJ Tentler, F Ciardiello, A Ryan, ... Molecular cancer therapeutics 8 (9), 2546-2558, 2009 | 50 | 2009 |
